B2BINPAY
6.6.2024 10:32:31 CEST | Business Wire | Press release
The industry-leading blockchain platform, B2BinPay, has improved even further. The most recent version offers clients more flexibility and efficiency by expanding blockchain functionality and introducing TRX staking. Let's review how these new features improve B2BinPay's user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606092849/en/
B2BinPay version 20 arrives with TRX staking feature and expanded blockchain support (Graphic: Business Wire)
TRX Staking – Earn While You Transact!
The launch of TRX Staking, based on the advanced Stake 2.0 mechanism developed by the TRON community, is a crucial highlight of B2BinPay v20. With its increased flexibility, simplified user interface, and improved resource delegation and utilisation efficiency, this new approach surpasses the previous Stake 1.0.
TRX staking empowers B2BinPay clients to stake any amount of TRX and earn a passive annual yield of 3-5% (subject to network conditions). But this is not all. By staking TRX, users can significantly reduce transaction fees on the TRON network. Staked TRX is converted into bandwidth and energy, two necessary resources, to achieve this.
Smart contracts run on energy, and transaction processing capability is provided by bandwidth. By staking TRX and acquiring these resources, companies and individuals can increase transaction efficiency and save operating costs, providing them a distinct competitive advantage.
Getting started with TRX Staking on B2BinPay is straightforward:
➔ Begin by converting your TRX into either Bandwidth or Energy based on the specific processing needs of your chosen asset type.
➔ After that, delegate your votes converted from Bandwidth or Energy to SR.
New Blockchains Supported
Building on the previous integration of Polygon and Avalanche, the addition of Optimism, Arbitrum, and Base—all of which provide native support for stablecoins—significantly broadens B2BinPay v20's support for blockchain technology.
Optimism
Optimism is a Layer 2 solution that scales the Ethereum leading network by batching transactions. It collects transaction data from the Ethereum blockchain, processes it in batches, and sends it back to the Ethereum mainnet for validation. Since its launch in 2021, Optimism has reduced fees by ten times compared to Ethereum's base level. Users have saved over $1 billion in gas payments, making it one of the most cost-effective blockchains.
Arbitrum
Arbitrum is an Ethereum scaling solution that increases transaction volumes while lowering costs. It shares Ethereum's tooling, enabling developers to deploy DApps on Arbitrum quickly and securely. This compatibility extends to stablecoins, offering users more choices.
Base
Base, developed by Coinbase, optimises Optimism’s OP Stack for enhanced EVM compatibility. This open-source rollup supports stablecoins and makes code deployment easier on Ethereum and compatible blockchains.
Why Does Expanded Blockchain Support Matter for Clients?
By incorporating additional blockchains, B2BinPay expands the range of transaction options, aligning with your business requirements using suitable technology. Specifically, B2BinPay now supports:
USDT on 7 networks: Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, and Arbitrum.
USDC on 8 networks: Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Bridged USDC on 4 networks: Avalanche, Polygon, Optimism, and Arbitrum.
Here are other use cases of how the blockchain expansion can benefit you.
Streamlining Withdrawals for End-Users
Suppose your end-user needs to withdraw funds in a currency that's not immediately available. In that case, B2BinPay allows for swift asset conversion to meet currency requirements and handle associated transaction fees, ensuring the timely fulfilment of withdrawal requests.
Reducing Blockchain Transaction Fees
If you aim to lower the cost of USDT transactions, B2BinPay offers an effective solution by allowing you to aggregate USDT from various blockchains, such as Ethereum or Optimism, into a single swap wallet.
Ensuring Liquidity for Trading Platforms
Suppose you have significant cryptocurrency funds and urgent requirements like stopouts on trading platforms. In that case, you can rely on B2BinPay's extensive blockchain support to quickly convert assets into the required currency for deposit. This feature assists you in maintaining liquidity and enables quick responsiveness to market demands.
Final Remarks
According to the official statements, Algorand and Solana will be introduced in the upcoming release. With this expansion, there will be 10 blockchains that enable stablecoin transactions, including those already used: Ethereum, Tron, Binance Smart Chain, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Connect with B2BinPay and unlock your business potential with advanced blockchain payment processing solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606092849/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom